685853-98-9

Basic information

• Product Name: 2-(4-METHYLPIPERAZIN-1-YL)-5-(TRIFLUOROMETHYL)ANILINE
• Synonyms: OTAVA-BB BB7110952507;AURORA 23302;2-(4-METHYLPIPERAZIN-1-YL)-5-(TRIFLUOROMETHYL)ANILINE;2-(4-METHYLPIPERAZINO)-5-(TRIFLUOROMETHYL)ANILINE;2-(4-METHYLPIPERAZINO)-5-(TRIFLUOROMETHYL)PHENYLAMINE;AKOS B033299
• CAS NO: 685853-98-9
• Molecular Formula: C₁₂H₁₆F₃N₃
• Molecular Weight: 259.27
• Mol File: 685853-98-9.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(4-METHYLPIPERAZIN-1-YL)-5-(TRIFLUOROMETHYL)ANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-METHYLPIPERAZIN-1-YL)-5-(TRIFLUOROMETHYL)ANILINE(685853-98-9)
• EPA Substance Registry System: 2-(4-METHYLPIPERAZIN-1-YL)-5-(TRIFLUOROMETHYL)ANILINE(685853-98-9)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 685853-98-9(Hazardous Substances Data)

Usage

Description

2-(4-METHYLPIPERAZIN-1-YL)-5-(TRIFLUOROMETHYL)ANILINE, also known as TAK-901, is a novel and potent small molecule inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) kinases. It is characterized by its unique chemical structure and mechanism of action, making it a promising candidate for the development of new cancer therapeutics.
Used in Pharmaceutical Industry:
2-(4-METHYLPIPERAZIN-1-YL)-5-(TRIFLUOROMETHYL)ANILINE is used as an anti-cancer agent for its ability to inhibit the activation of the IGF-1R and IR signaling pathways, which are implicated in the growth and survival of tumor cells. This makes it a potential treatment for various types of cancer, including breast, lung, and prostate cancer.
Used in Cancer Research:
2-(4-METHYLPIPERAZIN-1-YL)-5-(TRIFLUOROMETHYL)ANILINE is used as a research tool for studying the role of IGF-1R and IR signaling pathways in cancer development and progression. Its unique mechanism of action provides valuable insights into the development of new cancer therapeutics and the understanding of the molecular mechanisms underlying tumor growth and survival.

Upstream product

• 315239-67-9 1-methyl-4-(2-nitro-4-trifluoromethyl-phenyl)-piperazine 
• 109-01-3 1-methyl-piperazine 
• 367-86-2 1-fluoro-2-nitro-4-trifluoromethyl-benzene 

Downstream Products

• 926036-45-5 N-(2-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)phenyl)-2-fluoro-5-iodobenzamide 
• 1309358-91-5 N-[2-(4-methyl-1-piperazinyl)-5-(trifluoromethyl)phenyl]-1-phenylcyclo-propanecarboxamide 

Relevant articles and documents

Discovery of Novel Small-Molecule FAK Activators Promoting Mucosal Healing

Gastrointestinal mucosal wounds are common to patients injured by factors as diverse as drugs, inflammatory bowel disease, peptic ulcers, and necrotizing enterocolitis. However, although many drugs are used to ameliorate injurious factors, there is no drug available to actually stimulate mucosal wound healing. Focal adhesion kinase (FAK), a nonreceptor tyrosine kinase, induces epithelial sheet migration and wound healing, making FAK a potential pharmacological target in this regard. In our previous research, we found a lead compound with drug-like properties, ZINC40099027, which promotes FAK phosphorylation, inducing mucosal healing in murine models. Herein we describe the design and optimization of a small library of novel FAK activators based on ZINC40099027 and their applications toward human intestinal epithelial wound closure and mouse ulcer healing.

Novel pyrazole amide compound and preparation thereof, and application of novel pyrazole amide compound in prevention and treatment of plant pathogenic diseases and pest killing

The invention relates to a novel pyrazole amide compound I and a preparation method thereof and application of the novel pyrazole amide compound I in prevention and treatment of plant pathogenic disease and pest killing. The novel pyrazole amide compound

Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase

The recognition that aberrant angiogenesis contributes to the pathology of inflammatory diseases, cancer, and myocardial ischemia has generated considerable interest in the molecular mechanisms that regulate blood vessel growth. The receptor tyrosine kinase Tie-2 is expressed primarily by vascular endothelial cells and is critical for embryonic vasculogenesis. Interference with the Tie-2 pathway by diverse blocking agents such as soluble Tie-2 receptors, anti-Tie-2 intrabodies, anti-Ang-2 antibodies, and peptide-F c conjugates has been shown to suppress tumor growth in xenograft studies. An alternative strategy for interfering with the Tie-2 signaling pathway involves direct inhibition of the kinase functions of the Tie-2 receptor. Herein we describe the development of alkynylpyrimidine amide derivatives as potent, selective, and orally available ATP-competitive inhibitors of Tie-2 autophosphorylation.